Repatha patent expiration date?

Patent Status and Expiration

Repatha, also known as evolocumab, is a medication used to treat cholesterol issues. It is manufactured by Amgen and sold in collaboration with Sanofi [1]. The medication is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).

When Does the Patent Expire?

According to the website DrugPatentWatch.com, the United States patent for Repatha expires on February 10, 2041, for the original formulation [2]. However, patents for biosimilars and other formulations might expire earlier.

Biosimilars and Generic Versions

It is possible that biosimilars for Repatha may be approved before the patent expires. Biosimilars are versions of biologic medicines that mimic the original product and can have the same efficacy as the reference product. Amgen has a separate patent for their biosimilar version of Repatha, which can delay the entry of other biosimilar manufacturers into the market [3].

Timeline and Impact

The exact timeline for generic versions of Repatha entering the market depends on various factors, including regulatory approvals and patent disputes. Pharmaceutical companies have various strategies for protecting their intellectual property and maintaining market share.

References:

[1] Amgen. (n.d.). Repatha (evolocumab). Retrieved from https://www.amgen.com/our-science/our-medicines/repatha/

[2] DrugPatentWatch.com. (n.d.). Evolocumab (REPATHA). Retrieved from https://www.drugpatentwatch.com/drug/evolocumab

[3] Amgen. (n.d.). Repatha Biosimilar. Retrieved from https://www.amgen.com/our-science/our-medicines/repatha-biosimilar-1/

Sources:

1. Amgen. (n.d.). Repatha (evolocumab).
2. DrugPatentWatch.com. (n.d.). Evolocumab (REPATHA).
3. Amgen. (n.d.). Repatha Biosimilar.